Molecular Therapy-Methods & Clinical Development

Molecular Therapy-Methods & Clinical Development 由 Cell Press 出版，属中科院医学大类（2025 升级版2区）。按 OpenAlex 近年发文统计，该刊主要发表 Virus-based gene therapy research、CRISPR and Genetic Engineering、CAR-T cell therapy research 等主题的论文，这 3 个主题约占 47.2%，主导子领域为 Molecular Biology。（根据 OpenAlex 主题统计与中科院分区数据生成）

Molecular Therapy Advances is a peer-reviewed, open-access journal publishing transformative research across the full spectrum of gene and cell therapy. Formerly published as Molecular Therapy Methods & Clinical Development, the journal has evolved to reflect its expanded scope and renewed focus on field-defining science, from foundational discoveries to translational breakthroughs and early clinical advances. As an official journal of the American Society of Gene & Cell Therapy (ASGCT), it serves as a trusted platform for both ASGCT members and the broader scientific community.The journal reflects the accelerating pace of molecular medicine, where emerging technologies and cross-disciplinary approaches are reshaping the therapeutic landscape. We publish research that drives this momentum, emphasizing advances in gene delivery, genome and epigenome editing, engineered immune and stem cells, biomanufacturing, and both viral and non-viral vector platforms, alongside preclinical and clinical studies that move these innovations closer to patients. We also recognize the growing influence of computational science and artificial intelligence, which are redefining how therapies are designed, optimized and brought into clinical practice.We welcome studies across a broad range of diseases, from rare acquired and inherited disorders to more common conditions, when they offer meaningful mechanistic insight or therapeutic innovation. Submissions should demonstrate advancement in biological understanding, therapeutic potential, or translational impact. We particularly encourage work that challenges assumptions, reveals unexpected biology, or addresses persistent barriers in therapy development. High-quality negative results, replication studies, and methodological innovations are also valued when they strengthen rigor and reproducibility. Our mission is to elevate impactful science and provide a home for both established leaders and emerging voices shaping the future of gene and cell therapy.

摘自期刊官网 Aims & Scope

研究方向（LetPub）：Biochemistry, Genetics and Molecular Biology-Molecular Biology

中科院期刊分区表

数据库收录

ScopusDOAJLetPub

国际期刊预警名单：各版本均未列入LetPub

不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。

影响力指标

影响因子

5.04LetPub · 2026-09-13

影响因子（出版商公布）

5出版商官网 · 2026-10-01

CiteScore 2026-06

7.7LetPub · 2026-09-13

CiteScore（出版商公布）

7.7出版商官网 · 2026-10-01

SJR 2026-06

1.75LetPub · 2026-09-13

SNIP 2026-06

1.05LetPub · 2026-09-13

h-index

20LetPub · 2026-09-13

h-index

94OpenAlex · 2026-10-01

i10-index

1,207OpenAlex · 2026-10-01

两年平均被引

7.02OpenAlex · 2026-10-01

自引率

8%LetPub · 2026-09-13

Gold OA 文章占比

90.58%LetPub · 2026-09-13

发文规模

年文章数

148LetPub · 2026-09-13

不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。

其他来源

平均审稿速度（社区反馈）

12 WeeksLetPub · 2026-09-13

投稿到首次决定

7 天出版商官网 · 2026-10-01

外审后首次决定

43 天出版商官网 · 2026-10-01

投稿到接收

145 天出版商官网 · 2026-10-01

接收到发表

4 天出版商官网 · 2026-10-01

投稿到发表（期刊自报）

约 24 周DOAJ · 2026-10-11

评审方式

单盲同行评审DOAJ

社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。

• APC 费用说明 ↗DOAJ
• 费用减免政策 ↗DOAJ
• 开放获取声明 ↗DOAJ
• 许可与版权 ↗DOAJ

费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。

摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。

出版商

Cell Press

出版国家或地区

ENGLAND

出版语言

English

ISSN

2329-0501

电子版 ISSN

3117-387X

学会 / 主办单位

American Society of Gene & Cell Therapy

官方链接

• 期刊主页 ↗DOAJ
• 投稿系统 ↗出版商官网
• 作者指南 ↗DOAJ
• Aims & Scope ↗DOAJ
• 专刊 / 特刊征稿 ↗出版商官网
• APC 费用说明 ↗DOAJ
• 费用减免政策 ↗DOAJ
• 开放获取声明 ↗DOAJ
• 许可与版权 ↗DOAJ
• 评审流程 ↗DOAJ
• 编委会 ↗DOAJ
• 查重政策 ↗DOAJ